🔬 BE‑CAR7: Base‑Edited CAR‑T Therapy

What is it?

• BE‑CAR7 stands for Base-Edited CAR7 T cells, a form of chimeric antigen receptor (CAR) T‑cell therapy engineered to target the CD7 antigen on T cells (including malignant T cells) while avoiding self-targeting and immune rejection. [ashpublications.org], [nejm.org]

How it works:

• "7" refers to the CD7 antigen on T-cell surfaces.
• Healthy donor T-cells are base-edited using CRISPR-style cytidine deamination to inactivate:
  • TCR (prevents graft-versus-host disease)
  • CD7 (prevents CAR T cells from killing each other)
  • CD52 (evades certain immunosuppressive drugs). [ashpublications.org], [nejm.org]
• These modified cells are then transduced with a CAR that recognizes CD7 and infused into patients. [ashpublications.org], [nejm.org]

Clinical Trials & Results:

• Phase I trials (e.g., TvT CAR7, NCT05397184) have treated pediatric and adult patients with relapsed/refractory T‑ALL. [clinicaltrials.gov], [ashpublications.org]
• Early results published in New England Journal of Medicine:
  • Rapid deep remissions (some within 28 days)
  • 82% remission rate enabling subsequent stem cell transplant
  • ~64% disease-free survival at median 3-year follow-up. [nejm.org], [bloodcancer.org.uk], [packgene.com]
• Common side effects: cytokine release syndrome (mostly grade 1–2), cytopenias, infection—which are typical of CAR-T therapy. [ashpublications.org], [nejm.org]

Summary: What CAR7 Refers To

Broader Context

• While CA7 is also the symbol for Carbonic Anhydrase 7 (a brain-expressed enzyme), this is unrelated to CAR‑T therapies. [genecards.org], [informatics.jax.org]
• In automotive or other general contexts, CAR7 doesn't have a recognized meaning.

In summary:
“CAR7” refers to a cutting-edge, donor-derived, base-edited CAR‑T cell therapy engineered to treat CD7-positive T‑cell leukemias. It’s showing strong early evidence in clinical trials for achieving deep remission in relapsed/refractory T‑ALL patients.